AIkido Granted Sublicense to Technology for Targeted Psilocybin Treatment of Neuro-Inflamed Tissue in Cancer Patients

Rhea-AI Summary

AIkido Pharma Inc. (Nasdaq: AIKI) announced the acquisition of an exclusive sublicense for technology using central nervous system (CNS) homing peptides aimed at treating neuroinflammatory diseases in cancer patients. These peptides facilitate the targeted delivery of psilocybin, which has exhibited anti-inflammatory properties. CEO Anthony Hayes emphasized the potential of this technology for enhancing cancer treatment, complementing existing efforts in psilocybin research for PTSD at Mount Sinai. The company continues to develop a diverse portfolio of oncology therapies.

Positive

• Exclusive sublicense for CNS homing peptides to treat neuroinflammatory diseases.
• Potential for direct delivery of psilocybin to inflamed CNS tissue in cancer patients.
• Supports ongoing psilocybin research for PTSD at Mount Sinai.

Negative

• None.

NEW YORK, April 7, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that it has been granted an exclusive sublicense to technology related to the use of novel and proprietary central nervous system (CNS) homing peptides for the therapeutic treatment of neuroinflammatory disease in cancer patients.  

The homing peptides covered by the sublicense can be used to facilitate the delivery of therapeutic agents to inflamed CNS tissue.  Psychedelics such as psilocybin have been shown to have anti-inflammatory activity in addition to their potential efficacy for treatment of neurological disorders such as anxiety, depression and post-traumatic stress disorder (PTSD).  Studies indicate that neuroinflammation of the brain and other CNS tissues in cancer patients contributes to, among other symptoms, the onset of cancer cachexia, which is characterized by loss of appetite, extreme weight loss and muscle wasting. 

Anthony Hayes, CEO of AIkido Pharma, stated, "The novel homing peptides covered under this sublicense have the potential to allow the direct delivery of psilocybin to inflamed CNS tissue in cancer patients.  This sublicense culminates our Letter of Intent previously announced on February 16, 2021.  It complements our recently announced support of the psilocybin research for PTSD treatment at Mount Sinai Center for Psychedelic Psychotherapy and Trauma Research."

About AIkido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anti-cancer therapeutics.  The Company's platform consists of patented technology from leading universities and researchers, and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer and prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology.  The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations:      

Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com

AIkido Pharma Inc.:   

Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/aikido-granted-sublicense-to-technology-for-targeted-psilocybin-treatment-of-neuro-inflamed-tissue-in-cancer-patients-301264075.html

SOURCE AIkido Pharma Inc.

FAQ

What is the recent development by AIkido Pharma related to CNS technology?

AIkido Pharma has been granted an exclusive sublicense for technology involving CNS homing peptides to treat neuroinflammatory diseases in cancer patients.

How could the new peptides benefit cancer patients?

The peptides may facilitate the targeted delivery of psilocybin to inflamed CNS tissue, potentially improving treatment outcomes.

When was the sublicense agreement announced?

The sublicense agreement was announced on April 7, 2021.

What role does psilocybin play in AIkido's research?

Psilocybin is being researched for its anti-inflammatory properties and potential efficacy in treating neuroinflammatory conditions in cancer patients.

Does AIkido Pharma have ongoing research in PTSD treatment?

Yes, AIkido is supporting psilocybin research for PTSD treatment at Mount Sinai.